The global Morquio Syndrome (MPS-IV) drugs market size stood at USD 1,566 million in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
MPS-IV, refers to a rare inherited metabolic disorder or birth defect that mostly affects the skeleton. The FDA approval of VIMIZIM (elosulfase alpha), the first and the only specific treatment for the patients with this ultra-rare genetic condition, firmly established BioMarin’s position as a leading market player for the treatment of MPS diseases. Apart from the recent regulatory approvals, there has been increasing activity in the R&D for the Morquio syndrome treatment as evidenced by the greater inclusion of the disorder in the clinical pipelines of the major market players. For instance, Ultragenyx Pharmaceutical Inc. has a Phase 3 Study undergoing for the Morquio syndrome, Shire has an ongoing clinical trial for the pediatric patients suffering from the syndrome and ArmaGen, Inc. also has a drug (AGT-181) in the clinical trials. This combined with the greater awareness of the disease is also driving the growth in Morquio syndrome treatment market.
The growth in the number of products in the preliminary and advanced stages of R&D along with the focus on treatment of rare diseases is anticipated to drive the growth in the Morquio syndrome treatment market at a considerably fast rate. With the recent approval of the elosulfase alpha (VIMIZIM), the market is expected to be boosted several products currently in the pipeline of various companies can be anticipated to undergo regulatory approvals for the marketing, if they have favourable clinical trials results. Market players are more focused on adoption of inorganic growth strategies such as collaborations and partnerships to strengthen their position in the global mucopolysaccharidosis (MPS) treatment market. Adoption of inorganic growth strategies by key players is expected to drive the market growth over the forecast period.